Compare Stocks: PYPL, J, REGN, and UBS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
J Jacobs Solutions	$142.92 +3.0%	$126.54	$105.68 ▼ $168.44	$16.88B	0.68	1.06 million shs	1.36 million shs
PYPL PayPal	$58.54 +1.2%	$47.30	$38.46 ▼ $79.21	$50.08B	1.29	19.42 million shs	10.31 million shs
REGN Regeneron Pharmaceuticals	$760.66 +0.2%	$645.54	$541.00 ▼ $821.11	$80.42B	0.21	861,092 shs	817,234 shs
UBS UBS Group	$53.54 +1.5%	$50.38	$36.29 ▼ $55.15	$167.24B	1.18	2.42 million shs	1.72 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
J Jacobs Solutions	+2.62%	+2.60%	+8.55%	+1.83%	-0.37%
PYPL PayPal	+1.15%	+3.21%	+27.27%	+24.47%	-13.77%
REGN Regeneron Pharmaceuticals	-0.44%	+13.80%	+16.04%	+8.09%	+35.85%
UBS UBS Group	-0.01%	+0.43%	+3.43%	+19.60%	+43.85%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
J Jacobs Solutions	$142.92 +3.0%	$126.54	$105.68 ▼ $168.44	$16.88B	0.68	1.06 million shs	1.36 million shs
PYPL PayPal	$58.54 +1.2%	$47.30	$38.46 ▼ $79.21	$50.08B	1.29	19.42 million shs	10.31 million shs
REGN Regeneron Pharmaceuticals	$760.66 +0.2%	$645.54	$541.00 ▼ $821.11	$80.42B	0.21	861,092 shs	817,234 shs
UBS UBS Group	$53.54 +1.5%	$50.38	$36.29 ▼ $55.15	$167.24B	1.18	2.42 million shs	1.72 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
J Jacobs Solutions	+2.62%	+2.60%	+8.55%	+1.83%	-0.37%
PYPL PayPal	+1.15%	+3.21%	+27.27%	+24.47%	-13.77%
REGN Regeneron Pharmaceuticals	-0.44%	+13.80%	+16.04%	+8.09%	+35.85%
UBS UBS Group	-0.01%	+0.43%	+3.43%	+19.60%	+43.85%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
J Jacobs Solutions	2.50	Moderate Buy	$153.30	7.26% Upside
PYPL PayPal	2.11	Hold	$55.67	-4.91% Downside
REGN Regeneron Pharmaceuticals	2.70	Moderate Buy	$797.75	4.88% Upside
UBS UBS Group	2.36	Hold	$60.30	12.63% Upside

Current Analyst Ratings Breakdown

Latest PYPL, J, REGN, and UBS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/3/2026	PYPL PayPal	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$54.00 ➝ $60.00
8/3/2026	REGN Regeneron Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$700.00 ➝ $740.00
8/3/2026	REGN Regeneron Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$1,000.00 ➝ $1,030.00
7/31/2026	UBS UBS Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy (B)
7/31/2026	REGN Regeneron Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$696.00 ➝ $737.00
7/31/2026	REGN Regeneron Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$730.00 ➝ $758.00
7/31/2026	REGN Regeneron Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$750.00 ➝ $795.00
7/31/2026	REGN Regeneron Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$700.00 ➝ $750.00
7/31/2026	REGN Regeneron Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$769.00 ➝ $772.00
7/30/2026	UBS UBS Group	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Underweight
7/29/2026	PYPL PayPal	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$59.00 ➝ $65.00

(Data available from 8/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
J Jacobs Solutions	$12.03B	1.40	$8.71 per share	16.41	$30.52 per share	4.68
PYPL PayPal	$33.17B	1.51	$6.69 per share	8.75	$22.00 per share	2.66
REGN Regeneron Pharmaceuticals	$14.34B	5.61	$41.86 per share	18.17	$295.66 per share	2.57
UBS UBS Group	$76.12B	2.20	$3.67 per share	14.59	$28.96 per share	1.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
J Jacobs Solutions	$289.34M	$3.22	44.39	17.30	1.31	2.92%	22.29%	6.85%	8/4/2026 (Estimated)
PYPL PayPal	$5.23B	$5.29	11.07	10.09	1.42	14.36%	24.39%	6.06%	N/A
REGN Regeneron Pharmaceuticals	$4.50B	$40.46	18.80	18.00	28.06	27.86%	13.47%	10.34%	N/A
UBS UBS Group	$7.77B	$2.94	18.21	12.87	0.82	13.10%	10.50%	0.57%	N/A

Latest PYPL, J, REGN, and UBS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2026	Q3 2026	J Jacobs Solutions	$1.83	$1.84	+$0.01	$1.15	$2.40 billion	$2.42 billion
7/30/2026	Q2 2026	REGN Regeneron Pharmaceuticals	$10.16	$14.29	+$4.13	$12.23	$3.82 billion	$4.29 billion
7/29/2026	Q2 2026	UBS UBS Group	$0.90	$0.87	-$0.03	$0.87	$13.40 billion	$13.35 billion
7/28/2026	Q2 2026	PYPL PayPal	$1.28	$1.38	+$0.10	$1.25	$8.47 billion	$8.68 billion
5/5/2026	Q2 2026	J Jacobs Solutions	$1.64	$1.75	+$0.11	-$0.34	$2.28 billion	$2.33 billion
5/5/2026	Q1 2026	PYPL PayPal	$1.27	$1.34	+$0.07	$1.21	$8.05 billion	$8.35 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
J Jacobs Solutions	$1.44	1.01%	+28.17%	44.72%	4 Years
PYPL PayPal	$0.56	0.96%	N/A	10.59%	N/A
REGN Regeneron Pharmaceuticals	$3.76	0.49%	N/A	9.29%	N/A
UBS UBS Group	$0.36	0.67%	-100.00%	12.24%	5 Years

Latest PYPL, J, REGN, and UBS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/27/2026	PYPL PayPal	quarterly	$0.14	0.96%	9/4/2026	9/4/2026	9/25/2026
7/30/2026	J Jacobs Solutions	quarterly	$0.36	1.08%	8/21/2026	8/21/2026	9/18/2026
7/30/2026	REGN Regeneron Pharmaceuticals	quarterly	$0.94	0.51%	8/18/2026	8/18/2026	8/31/2026
5/4/2026	PYPL PayPal	Quarterly	$0.14	1.31%	6/4/2026	6/4/2026	6/25/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
J Jacobs Solutions	1.24	1.43	1.43
PYPL PayPal	0.55	1.29	1.29
REGN Regeneron Pharmaceuticals	0.06	3.34	2.78
UBS UBS Group	3.84	1.02	1.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
J Jacobs Solutions	85.65%
PYPL PayPal	68.32%
REGN Regeneron Pharmaceuticals	83.31%
UBS UBS Group	N/A

Insider Ownership

Company	Insider Ownership
J Jacobs Solutions	0.48%
PYPL PayPal	0.63%
REGN Regeneron Pharmaceuticals	6.97%
UBS UBS Group	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
J Jacobs Solutions	43,000	118.08 million	117.51 million	Optionable
PYPL PayPal	23,800	855.46 million	850.07 million	Optionable
REGN Regeneron Pharmaceuticals	15,410	105.72 million	98.35 million	Optionable
UBS UBS Group	103,177	3.12 billion	3.09 billion	Optionable

PYPL, J, REGN, and UBS Headlines

Recent News About These Companies

UBS sees further upside for Eurobank after outlook upgrade

3 hours ago | msn.com

UBS or TD: Which Is the Better Value Stock Right Now?

August 4 at 12:41 PM | zacks.com

Switzerland’s largest bank UBS fined $125M for anti-money laundering program violations

August 4 at 8:48 AM | msn.com

UBS Says Buy These 2 Chip Stocks as AI Demand Shows No Signs of Slowing

August 4 at 6:11 AM | tipranks.com

UBS Withdraws Substantial Holder Status in Lindian Resources

August 4 at 3:51 AM | tipranks.com

UBS Pays $125 Million to Settle US Charges of Repeated AML Failures

August 3 at 3:50 PM | pymnts.com

UBS Pays $125 Million to Settle US Charges of Repeated AML Failures

August 3 at 3:14 PM | pymnts.com

Why Universe Pharmaceuticals (UPC) Stock Is Up Today

August 3 at 3:10 PM | quiverquant.comQ

UBS fined $125mn over lax money laundering controls

August 3 at 12:12 PM | ft.com

Fund Update: New $17.9M $SCHX stock position opened by SAGESPRING WEALTH PARTNERS, LLC

August 3 at 10:31 AM | quiverquant.comQ

UBS Group AG $UBS Shares Sold by Bank of America Corp DE

August 3 at 3:12 AM | marketbeat.com

UBS Group AG Exits Substantial Shareholding in Artrya Limited

August 2 at 11:10 PM | tipranks.com

UBS Group Earnings Call Signals Profitable New Phase

August 2 at 8:30 PM | tipranks.com

UBS Group AG $UBS Stock Holdings Lessened by Groupe la Francaise

August 2 at 5:36 AM | marketbeat.com

Quantinno Capital Management LP Grows Position in UBS Group AG $UBS

August 2 at 5:19 AM | marketbeat.com

Healthcare of Ontario Pension Plan Trust Fund Makes New $1.25 Million Investment in UBS Group AG $UBS

August 2 at 5:04 AM | marketbeat.com

UBS Group AG $UBS Position Boosted by First Trust Advisors LP

August 2 at 3:43 AM | marketbeat.com

Groupama Asset Managment Has $11.26 Million Position in UBS Group AG $UBS

August 1 at 6:48 AM | marketbeat.com

UBS sees 2.2% decline in advisor headcount during the past 12 months

July 31, 2026 | investmentnews.comI

UBS raises forecast for nation’s GDP to expand 11 percent

July 31, 2026 | taipeitimes.comT

BIS Project Agorá settles $1 million in tokenized cross-border payment trials

July 31, 2026 | cointelegraph.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PYPL, J, REGN, and UBS Company Descriptions

Jacobs Solutions NYSE:J

$142.92 +4.20 (+3.03%)

Closing price 03:59 PM Eastern

Extended Trading

$141.91 -1.01 (-0.71%)

As of 05:23 PM Eastern

Jacobs Solutions Inc. provides consulting, technical, engineering, scientific, and project delivery services for the government and private sectors in the United States, Europe, Canada, India, Asia, Australia, New Zealand, the Middle East, and Africa. It operates through Critical Mission Solutions, People & Places Solutions, Divergent Solutions, and PA Consulting segments. The company offers cyber, data analytics, systems and software application integration and consulting, enterprise level and mission IT, design, nuclear, and enterprise level operations and maintenance services; software development, testing, mission integration, program management, research, development, test, evaluation services, training, and environmental remediation services; and other technical consulting solutions, as well as construction and construction management services. It also provides consulting services for consumer and manufacturing, defense and security, energy and utilities, financial services, government, health and life sciences, and transport industries. The company was founded in 1947 and is headquartered in Dallas, Texas.

PayPal NASDAQ:PYPL

$58.54 +0.67 (+1.16%)

Closing price 04:00 PM Eastern

Extended Trading

$58.50 -0.03 (-0.06%)

As of 05:45 PM Eastern

PayPal Holdings, Inc. operates a technology platform that enables digital payments on behalf of merchants and consumers worldwide. It operates a two-sided network at scale that connects merchants and consumers that enables its customers to connect, transact, and send and receive payments through online and in person, as well as transfer and withdraw funds using various funding sources, such as bank accounts, PayPal or Venmo account balance, PayPal and Venmo branded credit products comprising its installment products, credit and debit cards, and cryptocurrencies, as well as other stored value products, including gift cards and eligible rewards. The company provides payment solutions under the PayPal, PayPal Credit, Braintree, Venmo, Xoom, Zettle, Hyperwallet, Honey, and Paidy names. The company was founded in 1998 and is headquartered in San Jose, California.

Regeneron Pharmaceuticals NASDAQ:REGN

$760.66 +1.42 (+0.19%)

Closing price 04:00 PM Eastern

Extended Trading

$762.38 +1.72 (+0.23%)

As of 05:38 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

UBS Group NYSE:UBS

$53.54 +0.79 (+1.49%)

Closing price 03:59 PM Eastern

Extended Trading

$53.28 -0.25 (-0.47%)

As of 05:34 PM Eastern

UBS Group AG provides financial advice and solutions to private, institutional, and corporate clients worldwide. It operates through five divisions: Global Wealth Management, Personal & Corporate Banking, Asset Management, Investment Bank, and Non-core and Legacy. The company offers investment advice, estate and wealth planning, investing, corporate and banking, and investment management, as well as mortgage, securities-based, and structured lending solutions. It also provides personal banking products and services, such as deposits, credit and debit cards, and online and mobile banking, as well as lending, investments, retirement, and wealth management services; and corporate and institutional solutions, including equity and debt capital markets, syndicated and structured credit, private placements, leasing, traditional financing, and transaction banking solutions for payment and cash management services, trade and export finance, and global custody solutions. In addition, the company offers equities, fixed income, hedge funds, real estate and private markets, indexed and alternative beta strategies, asset allocation and currency investment strategies, customized multi-asset solutions, advisory and fiduciary services, and multi-manager hedge fund solutions and advisory services. Further, it advises clients on strategic business opportunities and helps them raise capital to fund their activities; enables its clients to buy, sell, and finance securities on capital markets and to manage their risks and liquidity; distributes, trades in, finances, and clears cash equities and equity-linked products; structures, originates, and distributes new equity and equity-linked issues; and originates, distributes, manages risk, and provides liquidity in foreign exchange, rates, credit and precious metals. The company was formerly known as UBS AG and changed its name to UBS Group AG in December 2014. UBS Group AG was founded in 1862 and is headquartered in Zurich, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PYPL, J, REGN, and UBS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PYPL, J, REGN, and UBS Earnings

Compare Dividends

Latest PYPL, J, REGN, and UBS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PYPL, J, REGN, and UBS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PYPL, J, REGN, and UBS Company Descriptions

Jacobs Solutions NYSE:J

PayPal NASDAQ:PYPL

Regeneron Pharmaceuticals NASDAQ:REGN

UBS Group NYSE:UBS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools